Humanized antibodies to ganglioside GM.sub.2

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5830470
SERIAL NO

08116778

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
KYOWA HAKKO KIRIN CO LTDTOKYO 100-8185

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanai, Nobuo Kanagawa, JP 97 2708
Hasegawa, Mamoru Kanagawa, JP 145 1396
Koike, Masamichi Tokyo, JP 34 447
Kuwana, Yoshihisa Tokyo, JP 31 516
Nakamura, Kazuyasu Tokyo, JP 84 2624
Shitara, Kenya San Diego, CA 83 2179

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation